Press Release

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jan. 5, 2005--Implant Sciences Corporation (AMEX: "IMX", "IMX.WS") a developer and manufacturer of products for the homeland security, semiconductor, and medical device industries, today announced orders for eight (8) additional QS-H100 hand-held explosives detection devices. The orders have been received from customers located in Europe and the Middle East. The Company has now received orders for fourteen (14) QS-H100 explosives detection devices and has qualified international prospects for an additional 39 units in Europe, the Middle East and Asia/Pacific countries.

The Company recently announced that personnel using the desktop version of the Quantum Sniffer(TM) ("QS(TM)") for car and cargo searches at the Athens International Airport are reporting favorable performance of our device. The detection of trace explosives at security checkpoints in most domestic airports is performed by rubbing a small piece of cloth, commonly referred to as a "swab", over articles to be evaluated, such as briefcase or handbag latches and zippers, in an attempt to collect trace "particles" of explosives. The swab is then placed into a device that utilizes a radioactive source in the detection process. In contrast, Implant Sciences' proprietary QS(TM) technology is, to the best of managements' knowledge, the only technology which detects pure vapors of explosives. In layman's terms, the QS(TM) technology is closest to replicating the "sniffing" ability of dogs. In addition, the QS(TM) does not use radioactive agents, and based on publicly available information, our devices take the least time to sample and analyze a target. The QS(TM) may be used to determine the presence of, or confirm the absence of, common explosives in personal equipment, packages, postal mail and cargo that may be conveyed by persons, vehicles, airplanes, and watercraft.

Dr. Anthony J. Armini, CEO of Implant Sciences Corporation, stated, "We are pleased to announce these additional international orders for our hand-held Quantum Sniffer(TM) explosives detection equipment. It is encouraging to see the acceptance of our new explosives detection products in such a short period of time since establishing our network of international distributors. We believe it is important that our explosives detection products appear to be attracting attention in important geographical areas such as Europe, the Middle East and the Asia/Pacific Rim."

Dr. Armini further stated, "On the domestic front, the government and military evaluation of the QS(TM) technology is progressing as expected. The Navy evaluation is ongoing and we continue to work cooperatively with them in their process. Further, strong interest in this new technology has been expressed from other key military and governmental agencies as well a private sector companies for building security, commercial cargo security, and personnel screening."

About Implant Sciences

Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top trace element detection devices toentify explosives. The Company has also received government grants from the US Army, Navy and Air Force, and the Transportation Security Administration to adapt the Company's explosive detection technology to a wide number of security requirements. The Company continues its efforts to develop new products and applications using its QS(TM) technology, including applications for the detection of explosives, narcotics and toxic materials.

Using its proprietary ion implantation and thin film coating technologies, Implant Sciences has a sophisticated production line that modifies the surface characteristics of orthopedic joint implants to reduce polyethylene wear, thereby substantially increasing the life of the implants. The Company also manufactures and markets radioactive and non-radioactive products for medical use, including radioactive seeds for treating prostate cancer that are distributed throughout the United States by its own direct sales force. In parallel with the production of these seeds, it is also developing additional brachytherapy products for the treatment of breast, eye, and other cancers.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "expect," "should," or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party distributors and sales representatives, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.